Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Guangzhou Baiyunshan Pharmaceutical Holdings (874 HK)
Watchlist
94
Analysis
Health Care
•
China
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. manufactures and sells Chinese patent medicine. The Company also wholesales, retails, imports, and exports Western and Chinese pharmaceutical products and various medical apparatus.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Quantitative Analysis
•
03 Nov 2024 10:05
A-H Premium Weekly (Nov 1st):Chalco, ZOOMLION, FDZJ, FLAT GROUP, RemeGen, CanSinoBIO
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Chalco, ZOOMLION, FDZJ, FLAT GROUP, RemeGen, CanSinoBIO.
Ke Yan, CFA, FRM
Follow
211 Views
Share
bearish
•
China Traditional Chinese Medicine
•
18 Oct 2024 23:12
China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price
This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...
Arun George
Follow
1k Views
Share
bullish
•
China Traditional Chinese Medicine
•
17 Oct 2024 00:34
China Traditional Chinese Medicine (570 HK): Theatre of the Absurd
The update will do little to soothe frayed nerves. The extension will be forthcoming as the delay is procedural, there is a reputational risk from...
Arun George
Follow
610 Views
Share
bullish
•
China Traditional Chinese Medicine
•
09 Oct 2024 14:13
China Traditional Chinese Medicine (570 HK): Never a Dull Moment as Profit Warning Lands
According to the Beijing Municipal Government website, China TCM has received unconditional approval from SAMR. This news was largely expected and...
Arun George
Follow
992 Views
Share
bullish
•
China Traditional Chinese Medicine
•
16 Aug 2024 01:32
China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls
The monthly update will relieve the bulls, but there remain potential stumbling blocks. Nevertheless, the risk vs. reward remains attractive.
Arun George
Follow
466 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.39.3
x